Kinase News and Research

RSS

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Ansaris announced today that it has received a milestone payment for the successful identification of a kinase-related compound under its drug discovery collaboration with Ono Pharmaceutical Co., Ltd. Ono will initiate the preclinical study of the identified compound. This collaboration between Ansaris and Ono was established to focus on the discovery of kinase-related compounds for the treatment of cancer, inflammatory and autoimmune diseases.

8 Feb 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Study finds contradictory role of RIP1 protein in the liver during sepsis

Researchers from Rhode Island Hospital have identified a protein that plays a dual role in the liver during sepsis. The protein, known as RIP1, acts both as a "death switch" and as a pro-survival mechanism. The ability to identify the triggers for these functions may play a key role in treating sepsis in the future. The study is published online in advance of print in the journal Shock.

3 Feb 2011

Agilent introduces first commercial RNA target enrichment system

Agilent Technologies, Inc., today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. The RNA capture kits make it possible to precisely measure expression levels of genes of interest and detect allelic-specific expression, splicing events and gene fusions.

3 Feb 2011

First commercially available full length human MTOR protein with superior biological activity released

OriGene Technologies, Inc., a gene-centric life sciences company, releases the first commercially available full length human MTOR protein with superior biological activity.

2 Feb 2011

EA sponsors research grant to investigate specific cancers and kinase mutations

Expression Analysis today announced a jointly sponsored research grant for up to eight American Cancer Society Grantees to investigate and draw parallels between specific cancers and recurring mutations in specific kinases, using targeted genome sequencing.

2 Feb 2011

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Positron emission tomography can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine.

1 Feb 2011

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Three of the world's top lung associations have published a new international multidisciplinary classification of lung adenocarcinoma, the first revision to the classification in six years.

1 Feb 2011

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

U-M researchers reveal molecular signals that regulate catch-up growth

University of Michigan researchers have uncovered molecular signals that regulate catch-up growth---the growth spurt that occurs when normal conditions are restored after a fetus, young animal or child has been ill, under stress or deprived of enough food or oxygen to grow properly.

29 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

Protein Erk necessary for nerve fibers to be wrapped with myelin

Researchers at the University of North Carolina at Chapel Hill have pinpointed a crucial function for a key player in the development of the nervous system. They found that this player - a protein called Erk - is necessary for nerve fibers to be wrapped with an insulating substance called myelin, which allows messages to be sent from the brain to the peripheral limbs and back again.

28 Jan 2011

API2-MALT1 fusion protein appears to trigger cancer

What happens when two proteins join together? In this case, they become like a power couple, where the whole is greater than the sum of the parts. API2 and MALT1 are two proteins that become fused together in a subset of lymphomas. The API2 part of the fusion connects with an enzyme called NIK. When it does, MALT1 comes in for the kill, splitting NIK in two, a process called cleavage.

28 Jan 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.

27 Jan 2011

p38-targeted compounds hold promise for Alzheimer's disease treatment

Linda J. Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, has been awarded a $750,000 grant to further her research into a possible treatment for Alzheimer's disease. The grant is from the Edward N. And Della L. Thome Memorial Foundation, and was one of only eight Awards in Alzheimer's Disease Drug Discovery Research to be given in the U.S. in 2010.

25 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Acetylation complex fits like a halo over a histone

To understand the emerging science of epigenetics-a field that describes how genes may be regulated without altering the underlying DNA itself-scientists are deciphering the many ways in which enzymes act on the proteins surrounding DNA within cells.

21 Jan 2011

Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma

Plexxikon today announced positive data from an interim analysis of the BRIM3 trial, a large multi-center Phase 3 clinical study of PLX4032 in patients with previously untreated metastatic melanoma with the BRAF mutation. Patients treated with PLX4032 had an improved overall survival compared to patients treated with dacarbazine, the current standard of care.

19 Jan 2011

Kinase News and Research

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Study finds contradictory role of RIP1 protein in the liver during sepsis

Agilent introduces first commercial RNA target enrichment system

First commercially available full length human MTOR protein with superior biological activity released

EA sponsors research grant to investigate specific cancers and kinase mutations

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Scientists to commence new DNA vaccine trial for use in patients with leukemia

U-M researchers reveal molecular signals that regulate catch-up growth

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

Protein Erk necessary for nerve fibers to be wrapped with myelin

API2-MALT1 fusion protein appears to trigger cancer

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

p38-targeted compounds hold promise for Alzheimer's disease treatment

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Acetylation complex fits like a halo over a histone

Positive results from PLX4032 Phase 3 Trial in patients with metastatic melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News